{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-116760","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.581330+00:00","generated_at":"2026-05-16T15:52:38.570416+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Citius Oncology launches LYMPHIR for CTCL; first marketed product","bullets":["LYMPHIR (denileukin diftitox-cxdl) now commercially available in U.S. for relapsed/refractory Stage I–III CTCL after prior systemic therapy.","Phase 3 pivotal study: ORR 36.2%, 84% skin tumor burden reduction, median response time 1.4 months, no cumulative toxicity.","Estimated U.S. market >$400M; permanent J-code (J9161) effective April 1, 2025; NCCN Category 2A recommendation.","International expansion via Integris Pharma distribution agreement for Southern Europe and Balkan countries.","Patient assistance program (Citius Advantage) and HCP portal (lymphirhcp.com) launched to support access."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-116760","json":"https://secwatch.observer/filing/0001213900-25-116760.json","markdown":"https://secwatch.observer/filing/0001213900-25-116760.md","text":"https://secwatch.observer/filing/0001213900-25-116760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025116760/0001213900-25-116760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390025116760/ea0267562-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:52:38.570416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}